Holen Sie sich die Stockscreener-App
1.81
0.00%
0.00
Handel nachbörslich:
1.80
-0.01
-0.55%
Schlusskurs vom Vortag:
$1.81
Offen:
$1.8
24-Stunden-Volumen:
1.90M
Relative Volume:
0.37
Marktkapitalisierung:
$270.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.1294
EPS:
-13.99
Netto-Cashflow:
$-12.56M
1W Leistung:
-4.23%
1M Leistung:
-15.81%
6M Leistung:
+56.03%
1J Leistung:
+21.48%
1-Tages-Spanne:
$1.775
$1.85
1-Wochen-Bereich:
$1.71
$1.96
52-Wochen-Spanne:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Vergleichen Sie PALI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.81 | 270.06M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-29 | Eingeleitet | Piper Sandler | Overweight |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat
Published on: 2026-01-19 10:30:24 - baoquankhu1.vn
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com South Africa
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com UK
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com India
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - ulpravda.ru
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 - The Manila Times
Palisade Bio Announces Strategic Equity Investment from the - GlobeNewswire
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Palisade Bio, Inc. (NASDAQ:PALI) Receives $20.50 Average Price Target from Analysts - Defense World
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Clear Str - MarketBeat
Piper Sandler Initiates Coverage on Palisade Bio (NASDAQ:PALI) - Defense World
9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria
Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - MarketScreener
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 By Investing.com - Investing.com South Africa
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - The Manila Times
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palisade Bio Inc-Aktie (PALI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):